JP2017537886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537886A5 JP2017537886A5 JP2017522375A JP2017522375A JP2017537886A5 JP 2017537886 A5 JP2017537886 A5 JP 2017537886A5 JP 2017522375 A JP2017522375 A JP 2017522375A JP 2017522375 A JP2017522375 A JP 2017522375A JP 2017537886 A5 JP2017537886 A5 JP 2017537886A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- optionally substituted
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 125000000623 heterocyclic group Chemical group 0.000 claims description 48
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 38
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000000304 alkynyl group Chemical group 0.000 claims description 27
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims 23
- 229940002612 prodrugs Drugs 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 239000011780 sodium chloride Substances 0.000 claims 23
- 239000012453 solvate Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 21
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims 8
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 7
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 150000004677 hydrates Chemical class 0.000 claims 5
- 230000000155 isotopic Effects 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 102000001253 Protein Kinases Human genes 0.000 claims 3
- 108060006633 Protein Kinases Proteins 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 150000002829 nitrogen Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 3
- 125000004434 sulfur atoms Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000002062 proliferating Effects 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 description 8
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 6
- -1 C 1-10 perhaloalkyl Chemical group 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- 229910004759 OSi Inorganic materials 0.000 description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067178P | 2014-10-22 | 2014-10-22 | |
| US62/067,178 | 2014-10-22 | ||
| PCT/US2015/056899 WO2016065138A1 (en) | 2014-10-22 | 2015-10-22 | Thiazolyl-containing compounds for treating proliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537886A JP2017537886A (ja) | 2017-12-21 |
| JP2017537886A5 true JP2017537886A5 (US07846941-20101207-C00217.png) | 2018-11-29 |
| JP6788583B2 JP6788583B2 (ja) | 2020-11-25 |
Family
ID=55761545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522375A Active JP6788583B2 (ja) | 2014-10-22 | 2015-10-22 | 増殖性疾患を処置するためのチアゾリル含有化合物 |
Country Status (7)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2932353A1 (en) | 2013-12-13 | 2015-06-18 | Steven P. Treon | Methods to treat lymphoplasmacytic lymphoma |
| CA2932351A1 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3209648B1 (en) | 2014-10-22 | 2020-03-11 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| WO2018013486A1 (en) * | 2016-07-14 | 2018-01-18 | Eli Lilly And Company | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
| ES2926153T3 (es) * | 2016-11-03 | 2022-10-24 | Corvus Pharmaceuticals Inc | Compuestos y métodos para modular la quinasa de células T inducible por interleucina-2 |
| KR102328682B1 (ko) * | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| CN109265455B (zh) * | 2018-11-09 | 2020-08-18 | 新发药业有限公司 | 一种达沙替尼的制备方法 |
| JOP20220199A1 (ar) * | 2020-02-26 | 2023-01-30 | Daewoong Pharmaceutical Co Ltd | طريقة لتحضير مشتقات أمين حلقي غير متجانس |
| WO2024111626A1 (ja) * | 2022-11-25 | 2024-05-30 | カルナバイオサイエンス株式会社 | 新規チアゾール誘導体 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| MXPA00010150A (es) | 1998-04-17 | 2002-05-14 | Parker Hughes Inst | Inhibidores de btk y metodos para su identificacion y uso. |
| TR200100300T2 (tr) | 1998-08-04 | 2001-07-23 | Astrazeneca Ab | Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri |
| PL346854A1 (en) | 1998-09-25 | 2002-03-11 | Astrazeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| JP4445262B2 (ja) | 2001-10-09 | 2010-04-07 | アムジェン インコーポレイテッド | 抗炎症剤としてのイミダゾール誘導体 |
| WO2004016597A2 (en) | 2002-08-14 | 2004-02-26 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| ES2571779T3 (es) | 2002-12-13 | 2016-05-26 | Ym Biosciences Australia Pty | Inhibidores de cinasa a base de nicotinamida |
| TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
| CA2589773A1 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| JP2008528585A (ja) * | 2005-01-26 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US7375951B2 (en) * | 2006-07-07 | 2008-05-20 | Lutron Electronics Co., Inc. | Load control device having a split enclosure |
| JP5305905B2 (ja) * | 2005-08-08 | 2013-10-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリミジンキナーゼ阻害剤 |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| WO2007059157A1 (en) | 2005-11-14 | 2007-05-24 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| PT2526933E (pt) | 2006-09-22 | 2015-06-23 | Pharmacyclics Inc | Inibidores da tirosina-quinase de bruton |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| JP5561702B2 (ja) * | 2007-08-02 | 2014-07-30 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼ調節剤および使用方法 |
| EP2508523B2 (en) * | 2007-10-23 | 2019-04-17 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
| WO2009076373A1 (en) * | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| CA2723237A1 (en) | 2008-05-06 | 2009-11-12 | Peter A. Blomgren | Substituted amides, method of making, and use as btk inhibitors |
| EP2331506B1 (de) | 2008-09-02 | 2013-07-03 | Boehringer Ingelheim International GmbH | Neue benzamide, deren herstellung und deren verwendung als arzneimittel |
| EP2365970B1 (en) | 2008-11-12 | 2018-03-21 | Gilead Connecticut, Inc. | Pyridazinones and their use as btk inhibitors |
| RU2012112151A (ru) | 2009-09-03 | 2013-10-10 | Аллерган, Инк. | Соединения как модуляторы тирозинкиназы |
| WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CA2802641C (en) | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| CA2815330A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| EP2640366A2 (en) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| SI2714677T1 (sl) | 2011-05-23 | 2018-12-31 | Merck Patent Gmbh | Piridinski in pirazinski derivati |
| EA031153B1 (ru) * | 2011-06-10 | 2018-11-30 | Мерк Патент Гмбх | Применение пиримидиновых соединений с btk ингибирующей активностью |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US9023873B2 (en) | 2011-10-03 | 2015-05-05 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| MX2014005289A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de piperazina alquilados. |
| AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
| WO2013088404A1 (en) | 2011-12-15 | 2013-06-20 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| CN103405429A (zh) | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| CA2932351A1 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| CA2932353A1 (en) | 2013-12-13 | 2015-06-18 | Steven P. Treon | Methods to treat lymphoplasmacytic lymphoma |
| EP3209648B1 (en) | 2014-10-22 | 2020-03-11 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
-
2015
- 2015-10-22 EP EP15852450.4A patent/EP3209648B1/en active Active
- 2015-10-22 WO PCT/US2015/056899 patent/WO2016065138A1/en active Application Filing
- 2015-10-22 JP JP2017522375A patent/JP6788583B2/ja active Active
- 2015-10-22 AU AU2015335788A patent/AU2015335788B2/en active Active
- 2015-10-22 US US15/518,541 patent/US10112957B2/en active Active
- 2015-10-22 EP EP20161511.9A patent/EP3715346B1/en active Active
- 2015-10-22 CA CA2965178A patent/CA2965178C/en active Active
-
2017
- 2017-04-19 IL IL251790A patent/IL251790B/en active IP Right Grant
-
2018
- 2018-10-24 US US16/169,972 patent/US10464949B2/en not_active Expired - Fee Related
-
2019
- 2019-11-01 US US16/672,198 patent/US10844077B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537886A5 (US07846941-20101207-C00217.png) | ||
| JP2017537940A5 (US07846941-20101207-C00217.png) | ||
| CA3080808A1 (en) | Modulators of the integrated stress pathway | |
| JP2010509375A5 (US07846941-20101207-C00217.png) | ||
| HU229076B1 (en) | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties | |
| JP2018528261A5 (US07846941-20101207-C00217.png) | ||
| JP2017528467A5 (US07846941-20101207-C00217.png) | ||
| JP2017533922A5 (US07846941-20101207-C00217.png) | ||
| JP2018536641A5 (US07846941-20101207-C00217.png) | ||
| JP2014503574A5 (US07846941-20101207-C00217.png) | ||
| JP2016525121A5 (US07846941-20101207-C00217.png) | ||
| JP2014502266A5 (US07846941-20101207-C00217.png) | ||
| JP2019524883A5 (US07846941-20101207-C00217.png) | ||
| BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
| BR112021006789A2 (pt) | moduladores de produto da via integrada de estresse | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| JP2013530179A5 (US07846941-20101207-C00217.png) | ||
| JP2016516043A5 (US07846941-20101207-C00217.png) | ||
| EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| WO2018075959A4 (en) | Methods using hdac11 inhibitors | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| JP2011517683A5 (US07846941-20101207-C00217.png) | ||
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| JP2016513696A5 (US07846941-20101207-C00217.png) |
